Patent · US Active

Anti-IL-12/IL-23 antibodies

US8563697B2 · kind B2 · utility

6Cited by

108References

11Claims

0Family size

Assignee

Cephalon Australia Pty. Ltd. · AU

Inventors

Adam Clarke · Chatswood, AU
Anthony G. Doyle · Chatswood, AU
Philip Anthony Jennings · Chatswood, AU
Lynn Dorothy Poulton · Chatswood, AU
Bernadette Wai · Parramatta, AU
Andrew James Pow · Burlingame, US
George Kopsidas · Preston, AU

Key dates

Filing date	Aug 14, 2009
Grant date	Oct 22, 2013
Priority date	—
Expiry date	Aug 14, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R β2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.